{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:58:28Z","timestamp":1792735108498,"version":"4.5.0"},"reference-count":84,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The oral Janus kinase (JAK) 1\/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU). PV is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and JAK mutations such as <jats:italic>JAK2<\/jats:italic>V617F. Patients with PV experience burdensome symptoms and are at risk of thromboembolic events, in particular those with resistance to or intolerance of initial treatments such as HU. Other risks for patients with PV include progression of disease to more aggressive forms with worse prognoses, such as myelofibrosis or blast\u2010phase myeloproliferative neoplasms. This review summarizes the efficacy and safety of ruxolitinib from key phase 2 and 3 trials (MAJIC\u2010PV, RESPONSE, RESPONSE\u20102, RELIEF, and Ruxo\u2010BEAT), large real\u2010world studies, and a decade of postmarketing surveillance safety data. The authors focus on improved blood count control, rates of thromboembolic events, symptom improvement, and markers of disease modification such as reduction of <jats:italic>JAK2<\/jats:italic>V617F allele burden in patients treated with ruxolitinib. They also discuss the well\u2010characterized safety profile of ruxolitinib regarding hematologic and other adverse events of interest. In the 10 years since its approval, ruxolitinib remains a safe and effective standard\u2010of\u2010care treatment for PV. As the treatment landscape for PV continues to evolve in the coming years, the efficacy and safety profiles of ruxolitinib suggest it will remain a preferred treatment as monotherapy and as a potential backbone of future combination regimens.<\/jats:p>","DOI":"10.1002\/cncr.35661","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T03:00:42Z","timestamp":1733022042000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Hu","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Livingston","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010643544"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.42.3863"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010016\u20102208\u20102"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106809"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/m17\u20100028"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201005\u2010579136"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221234"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.42.1925"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090299"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19557"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18650"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.759656"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201004\u2010638593"},{"key":"e_1_2_6_15_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms version 1.2024. Accessed August 9 2024.https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1477"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201001\u2010478891"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1208500"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16380"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010023\u201005089\u20106"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13886"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201010\u2010387787"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2009.08019.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010019\u201003654\u20106"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13291"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.1.47"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.601"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_6_28_1","volume-title":"Full Prescribing Information","author":"JAKAFI (ruxolitinib)","year":"2023"},{"key":"e_1_2_6_29_1","unstructured":"US Food and Drug Administration.FDA approves Jakafi to treat patients with chronic type of bone marrow disease: first FDA\u2010approved drug for polycythemia vera. Accessed June 11 2024.https:\/\/news.bloomberglaw.com\/pharma\u2010and\u2010life\u2010sciences\/fda\u2010approves\u2010jakafi\u2010to\u2010treat\u2010patients\u2010with\u2010chronic\u2010type\u2010of\u2010bone\u2010marrow\u2010disease"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020232"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(19)30207\u20108"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1409002"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(16)30558\u20107"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00102\u20108"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01935"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201005080\u20107"},{"key":"e_1_2_6_37_1","unstructured":"KoschmiederS lsfortS TeichmannLL et al.Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera. Paper presented at: 65th American Society of Hematology (ASH) Annual Meeting and Exposition; December 9\u201012 2023; San Diego CA."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14382"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143644"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22789"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102004\u201007\u20102864"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100019\u2010y"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010020\u20102864\u2010x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017697"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002271"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201009\u2010176818"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa035572"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021444"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(20)30373\u20102"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021503"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010017\u20102994\u2010x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27400"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1619"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235648"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.020"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14124"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000971024.48080.f5"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004815\u2010w"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34195"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.023"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.019"},{"key":"e_1_2_6_63_1","article-title":"Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control","author":"US Food and Drug Administration","year":"2024","journal-title":"Guidance for Industry"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001471\u2010z"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24976"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201003\u2010484642"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1090"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000793"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201053056\u2010x"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003050"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2843"},{"key":"e_1_2_6_72_1","volume-title":"Summary of product characteristics","author":"JAKAVI (ruxolitinib)","year":"2024"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u201001\u2010897637"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13751"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100954\u20102"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2361836"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281\u2010018\u20100700\u20102"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201007\u2010442012"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061390"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010157397"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2199151"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.11.004"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010149219"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000747"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:00:24Z","timestamp":1760266824000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cncr.35661"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35661","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35661"}}